Furthermore, to assess the therapeutic potential of reducing the level of MaTAR25 in vivo, we evaluated the impact of subcutaneous injection of two independent MaTAR25 ASOs for their in vivo ability to knockdown MaTAR25 and to impact mammary tumor progression in the MMTV-Neu-NDL mouse model. The gene discussed is ERBB2; the disease is breast cancer.